Aroa Biosurgery Limited (ASX: ARX) - Share Price
Current share price for ARX : $0.585 0.015 (2.50%)+
Aroa Biosurgery Limited (ARX), an ASX-listed company, is a soft-tissue regeneration company that develops, manufactures and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction.
ARX General Information +
| ASX Code | ARX |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 202 |
| ARX Share Price | $0.585 |
| Day High | $0.605 |
| Day Low | $0.585 |
| Last Close | $0.600 |
| ARX Share Price Movement | $0.02 ( 2.50% ) |
Prices as at 16:40, 17 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Aroa Biosurgery Limited (ARX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Aroa Biosurgery Limited (ARX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Aroa Biosurgery Limited (ARX) price-sensitive announcements
ARX - FY26 Full Year Results Presentation
The FY26 Full Year Results Presentation for Aroa Biosurgery Limited focuses on financial p
Aroa Biosurgery Limited (ARX)
26 May 2026 | 8:51 AM
26 May 2026 | 8:51 AM
ARX - FY26 Appendix 4E and Full Year Results
Aroa Biosurgery Limited, a company specializing in soft-tissue regeneration, announced its
Aroa Biosurgery Limited (ARX)
26 May 2026 | 8:48 AM
26 May 2026 | 8:48 AM
ARX - ARX FY26 Preliminary Results
Aroa Biosurgery Limited has announced preliminary unaudited results for the fiscal year en
Aroa Biosurgery Limited (ARX)
30 Apr 2026 | 8:24 AM
30 Apr 2026 | 8:24 AM
ARX - Symphony Randomised Control Trial Complete
Aroa Biosurgery Limited announced the completion of its Symphony randomised controlled tri
Aroa Biosurgery Limited (ARX)
30 Mar 2026 | 9:15 AM
30 Mar 2026 | 9:15 AM
Aroa Biosurgery Limited (ARX) Recent ASX Announcements
ARX Financial Summary
| Year to Mar | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2028F | C2 | $1.70 | 101.20% | 35.50 | 0.00 | 0.00% | 0.0% |
| 2027F | C2 | $0.80 | -24.10% | 71.30 | 0.00 | 0.00% | 0.0% |
| 2026A | $3.90 | $1.10 | -208.00% | 57.00 | 0.00 | 0.00% | 0.0% |
ARX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 A | 2027 F | 2028 F | 2026 A | 2027 F | 2028 F | 2026 A | 2027 F | 2028 F | ||
| Aroa Biosurgery Limited (ARX) | $208M | -2.0800 | -0.2407 | 1.0122 | 55.5556 | 73.1707 | 36.3636 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $58,403M | 0.1108 | -0.1189 | 0.0168 | 13.0768 | 14.8421 | 14.5973 | 3.66% | 2.99% | 3.11% |
| Clinuvel Pharmaceuticals Limited (CUV) | $510M | 0.0287 | 0.0000 | 0.0000 | 14.0808 | 0.0000 | 0.0000 | 0.49% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $3,592M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,304M | -1.3893 | 0.0000 | -0.1300 | 0.0000 | 285.8974 | 328.6316 | 0.00% | 0.00% | 0.00% |
ARX Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Brian Roderick Ward | Chief Executive Officer, Managing Director | 21 Sep 2007 |
| Mr James (Jim) Neil McLean | Non-Executive Chairman, Non-Executive Director | 10 Aug 2011 |
| Mr John Flower Diddams | Non-Executive Director | 21 Nov 2019 |
| Mr Philip John McCaw | Non-Executive Director | 5 Mar 2008 |
| Mr Paul N Shearer | Non-Executive Director | 31 Oct 2025 |
| Dr Catherine Mohr | Non-Executive Director | 1 Nov 2022 |
| Ms Darla Hutton | Non-Executive Director | 22 Mar 2024 |
Aroa Biosurgery Limited (ARX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 26 Jun 2026 | DIDDAMS, John | Sell | Indirect Shares | 200,000 | $0.629 | $125,789.040 |
| 6 Jun 2025 | DIDDAMS, John | Sell | Indirect Shares | 160,000 | $0.484 | $77,474.960 |
| 30 Sep 2024 | MOHR, Catherine | Buy | Indirect Shares | 436,364 | $0.375 | $163,453.670 |
See all changes in directors' interest & trades for Aroa Biosurgery Limited (ARX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ARX Management
| Name | Position |
|---|---|
| James Blair Agnew | Chief Financial Officer,Joint Company Secretary |
| Yasmin Winchester | Chief of Technical Operations |
| Rod Stanley | Chief Operating Officer |
| Dr. Barnaby May | Chief Scientific Officer |
| Tracy Weimar | Joint Company Secretary |
ARX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Aroa Biosurgery Limited (ARX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 33,125,800 (9.58%) | Brian Ward |
| 30,421,199 (8.79%) | FirstCape Group Limited |
| 29,842,804 (7.57%) | Acorn Capital Limited |
| 20,077,154 (5.80%) | Phil McCaw |
| 17,288,432 (5%) | State Street Australia Ltd |
ARX Calendar of Events
| Date | Event |
|---|---|
| 29 June 2027 | Report (Annual) |
| 25 May 2027 | Report (Prelim) |
| 24 November 2026 | Report (Interim) |
| 19 August 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
